A Real-World Approach to the Early Identification of TIL Patient Candidates
- Fast-tracking TIL for patients unlikely to benefit from checkpoint inhibitors
- Minimizing immune exhaustion from prolonged immunotherapy exposure
- Enhancing referral networks to reach patients beyond major treatment centers